Zobrazeno 1 - 8
of 8
pro vyhledávání: '"Michael Pantze"'
Effect of erlotinib on CYP3A activity, evaluated in vitro and by dual probes in patients with cancer
Autor:
Hilary Calvert, Chris Twelves, Malcolm Ranson, Ruth Plummer, Scott Fettner, Michael Pantze, Jie Ling, Marta Hamilton, Bert L. Lum, Ashok Rakhit
Publikováno v:
Anti-Cancer Drugs. 25:832-840
In vitro, erlotinib (0-30 µmol/l) and C-labelled midazolam (MDZ) (5 µmol/l) were incubated with human liver microsomes; separately, microsomes were preincubated with erlotinib (10 µmol/l) before the addition of MDZ. Results showed a time-dependent
Autor:
Yanan Zheng, Jihong Yang, Nicholas Lewin-Koh, Oliver Boris Stauch, Jane Ruppel, Sami McVay, Wendy S. Putnam, Leslie A. Khawli, Paul J. Fielder, Lisa J. Benincosa, C. Andrew Boswell, Kyra J. Cowan, Jing Li, Frank-Peter Theil, Jennifer O’Mahony, Wolfgang F. Richter, Herbert Birnböck, Hans Peter Grimm, Ann L. Daugherty, Thomas Singer, Daniela Bumbaca, Michael Pantze, Dimitry M. Danilenko, Michael B. Otteneder, Devin Tesar, Gerry Kolaitis, Jennifer Visich, Yong Ying, Zhihua J. Qiu, Amita Joshi, Nicole Justies
Publikováno v:
mAbs. 4:243-255
Subcutaneous (SC) delivery is a common route of administration for therapeutic monoclonal antibodies (mAbs) with pharmacokinetic (PK)/pharmacodynamic (PD) properties requiring long-term or frequent drug administration. An ideal in vivo preclinical mo
Autor:
Myriam Riek, Bert L. Lum, Jean-Eric Charoin, Hannah M. Jones, Michael Pantze, Scott Fettner, Marta Hamilton, Ashok Rakhit
Publikováno v:
European Journal of Clinical Pharmacology. 64:31-41
Erlotinib is an orally active antitumor agent. Analyses in vitro using human liver microsomes and recombinant enzymes showed that erlotinib was metabolized primarily by CYP3A4, with a secondary contribution from CYP1A2.A computer-based simulation mod
Autor:
Zhuang Miao, Bert L. Lum, Ashok Rakhit, Michael Pantze, Marta Hamilton, Jie Ling, Kim A. Johnson, Chandra Prakash
Publikováno v:
Drug Metabolism and Disposition. 34:420-426
Metabolism and excretion of erlotinib, an orally active inhibitor of epidermal growth factor receptor tyrosine kinase, were studied in healthy male volunteers after a single oral dose of [14C]erlotinib hydrochloride (100-mg free base equivalent, appr
Autor:
Gerd Scheuermann, Mirjana Lazendic, Michael Pantze, Linda Jehle, Christiane Ponelle, Christoph Funk, Rodolfo Gasser
Publikováno v:
Toxicology. 167:83-98
Troglitazone is a thiazolidinedione insulin sensitizer drug for the treatment of type 2 non-insulin-dependent diabetes mellitus (NIDDM). Based on an increasing number of reports on troglitazone-associated liver toxicity, the cholestatic potential of
Autor:
Michael Pantze, Bruno Stieger, Christoph Funk, Peter J. Meier, Cornelia Weber, Karin Fattinger, Jürg Reichen
Publikováno v:
Clinical Pharmacology & Therapeutics. 69:223-231
BACKGROUND: During clinical trials bosentan, the first orally active endothelin receptor antagonist, caused asymptomatic transaminase elevations in some patients. In this study we investigated whether inhibition of the hepatocanalicular bile salt exp
Autor:
Michael Pantze, Uwe Timm, Christoph Funk, Manfred Zell, Axel Paehler, Idelette Weick, Olaf Kuhlmann
Publikováno v:
Xenobiotica; the fate of foreign compounds in biological systems. 40(12)
The pharmacokinetics and excretion of carmegliptin, a novel dipeptidyl peptidase IV inhibitor, were examined in rats, dogs, and cynomolgus monkeys. Carmegliptin exhibited a moderate clearance, extensive tissue distribution, and a variable oral bioava
Autor:
Christiane Lamy, Christoph Funk, Johannes Noe, Rubén Alvarez-Sánchez, Axel Paehler, Florian Klammers, Michael Pantze, Renée Portmann
Publikováno v:
Hepatotoxicity
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::d55c07cd5b7a1241c658fcda2cd9a603
https://doi.org/10.1002/9780470516751.ch16
https://doi.org/10.1002/9780470516751.ch16